Latest period
138M
YoY change
+5.5%
5Y CAGR
+3.2%
Peak year (FY2025)
135M
Latest annual
135M
Shares Outstanding history chart for Alnylam Pharmaceuticals (ALNY) from 2016 to 2025
Latest: 135M
Shares Outstanding growth chart for Alnylam Pharmaceuticals (ALNY) from 2016 to 2025
Latest: +5.5%
Shares Outstanding history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| FY2025 | 135M | +5.5% | +7.03M | ||
| FY2024 | 128M | +2.2% | +2.75M | ||
| FY2023 | 125M | +2.6% | +3.22M | ||
| FY2022 | 122M | +2.7% | +3.24M | ||
| FY2021 | 118M | +3.0% | +3.47M | ||
| FY2020 | 115M | +5.2% | +5.72M | ||
| FY2019 | 109M | +8.6% | +8.67M | ||
| FY2018 | 101M | +11.1% | +10M | ||
| FY2017 | 90.6M | +5.8% | +4.96M | ||
| FY2016 | 85.6M | +1.9% | +1.6M | ||
| FY2015 | 84M | +13.1% | +9.71M | ||
| FY2014 | 74.3M | +20.7% | +12.7M | ||
| FY2013 | 61.6M | +22.4% | +11.3M | ||
| FY2012 | 50.3M | +18.6% | +7.88M | ||
| FY2011 | 42.4M | +0.9% | +370K | ||
| FY2010 | 42M | +1.0% | +407K | ||
| FY2009 | 41.6M | +1.4% | +556K | ||
| FY2008 | 41.1M | +6.3% | +2.42M | ||
| FY2007 | 38.7M | +21.2% | +6.77M | ||
| FY2006 | 31.9M | +45.3% | +9.94M | ||
| FY2005 | 21.9M | +84.7% | +10.1M | ||
| FY2004 | 11.9M | +1160.9% | +10.9M | ||
| FY2003 | 943K | +184.5% | +611K | ||
| FY2002 | 331K | — | — |
- FY2025135M+5.5%
- FY2024128M+2.2%
- FY2023125M+2.6%
- FY2022122M+2.7%
- FY2021118M+3.0%
- FY2020115M+5.2%
- FY2019109M+8.6%
- FY2018101M+11.1%
- FY201790.6M+5.8%
- FY201685.6M+1.9%
- FY201584M+13.1%
- FY201474.3M+20.7%
- FY201361.6M+22.4%
- FY201250.3M+18.6%
- FY201142.4M+0.9%
- FY201042M+1.0%
- FY200941.6M+1.4%
- FY200841.1M+6.3%
- FY200738.7M+21.2%
- FY200631.9M+45.3%
- FY200521.9M+84.7%
- FY200411.9M+1160.9%
- FY2003943K+184.5%
- FY2002331K—
Shares Outstanding values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Shares Outstanding at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported diluted shares outstanding is 138M. Diluted weighted-average shares outstanding is the share count used to compute per-share metrics like EPS. Buybacks lower it; new issuance, stock-based compensation, and convertible securities raise it. Multiply by the stock price for market capitalization.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual diluted shares outstanding for Alnylam Pharmaceuticals (ALNY) came in at 135M – grew 5.5% year-over-year.
Alnylam Pharmaceuticals diluted shares outstanding compound annual growth for the 2020–2025 (5 years) window is +3.2%, sustaining 23 straight years of year-over-year growth.
2025 marks the peak diluted shares outstanding at 135M, with the historical low of 331K recorded in 2002.
Alnylam Pharmaceuticals Shares Outstanding by Year
Alnylam Pharmaceuticals Shares Outstanding 2025: 135M
Alnylam Pharmaceuticals diluted shares outstanding in 2025 was 135M, grew 5.5% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Shares Outstanding 2024: 128M
2024's diluted shares outstanding for Alnylam Pharmaceuticals came in at 128M, edged up 2.2% from 2023.
Alnylam Pharmaceuticals Shares Outstanding 2023: 125M
Alnylam Pharmaceuticals posted diluted shares outstanding of 125M in 2023, edged up 2.6% from 2022.
Alnylam Pharmaceuticals Shares Outstanding 2022: 122M
In 2022, Alnylam Pharmaceuticals reported diluted shares outstanding of 122M, edged up 2.7% from 2021.
Alnylam Pharmaceuticals Shares Outstanding 2021: 118M
Alnylam Pharmaceuticals diluted shares outstanding in 2021 was 118M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Shares Outstanding
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest diluted shares outstanding
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.